Medicare Enrolled
Dr. Salvatore Napoli, M.D.
Neurology · Foxboro, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Napoli from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Napoli?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Napoli
Dr. Salvatore Napoli is a neurology specialist in Foxboro, MA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Napoli performed 85,336 Medicare services across 1,134 unique beneficiaries.
Between the years covered by Open Payments, Dr. Napoli received a total of $699,260 from 76 pharmaceutical and/or device companies across 1371 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Napoli is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 0% volume in MA
$699,260 industry payments
Medicare Practice Summary
Medicare Utilization ↗85,336
Medicare services
Top 0% in MA for neurology
1,134
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,491 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Ocrelizumab infusion (Ocrevus) for MS | 33,604 | $40 | $104 |
| Botox injection, per unit An injection of onabotulinumtoxinA, a medication used to temporarily relax muscles or reduce gland activity. The dose is measured in units, with this code representing a single unit administered. |
23,619 | $5 | $10 |
| Injection, natalizumab, 1 mg | 19,263 | $18 | $38 |
| Injection, eptinezumab-jjmr, 1 mg | 3,313 | $13 | $120 |
| Injection, tildrakizumab, 1 mg | 2,804 | $110 | $607 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
362 | $139 | $408 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
356 | $100 | $312 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
307 | $4 | $18 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
295 | $116 | $450 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
215 | $23 | $180 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
165 | $43 | $124 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
162 | $55 | $198 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
148 | $46 | $154 |
| Bilateral facial and neck nerve muscle paralysis injection Injection of a chemical agent to paralyze muscles in the face and neck on both sides. |
142 | $128 | $450 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
135 | $13 | $60 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
70 | $18 | $66 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
63 | $12 | $72 |
| Remote vital sign monitoring management, each additional 20 minutes This code covers the time spent by a provider managing patient data from remote vital sign monitoring devices. It applies to each additional 20-minute increment beyond the initial monthly service period. |
60 | $34 | $145 |
| Anti-nausea injection (ondansetron/Zofran) | 60 | $0 | $36 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
39 | $74 | $240 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
37 | $0 | $48 |
| New patient office visit, complex (60-74 min) | 36 | $173 | $540 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
36 | $1 | $48 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
30 | $54 | $101 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
15 | $78 | $660 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
40.0% high complexity
58.6% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$699,260
Total received (2018-2024)
Avg $99,894/year across 7 years
Top 1% in MA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
76
Companies
1,371
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$642,727 (91.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$43,038 (6.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,495 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$86,186
2023
$106,469
2022
$81,497
2021
$67,779
2020
$77,859
2019
$131,811
2018
$147,659
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TG Therapeutics, Inc.
$17,440
EMD Serono, Inc.
$16,121
Eisai Inc.
$13,756
Biogen, Inc.
$13,726
Mallinckrodt Hospital Products Inc.
$9,185
Merck Sharp & Dohme LLC
$4,185
GENZYME CORPORATION
$3,658
E.R. Squibb & Sons, L.L.C.
$2,961
ANI Pharmaceuticals, Inc.
$2,450
Lundbeck LLC
$504
ModernaTX, Inc.
$500
SK Life Science, Inc.
$401
Celgene Corporation
$393
Amgen Inc.
$253
PFIZER INC.
$138
ABBVIE INC.
$136
Novartis Pharmaceuticals Corporation
$134
Genentech USA, Inc.
$68
Alexion Pharmaceuticals, Inc.
$41
Otsuka America Pharmaceutical, Inc.
$40
Kyowa Kirin, Inc.
$18
AstraZeneca Pharmaceuticals LP
$18
Vanda Pharmaceuticals Inc.
$18
Mylan Specialty L.P.
$14
Neurelis, Inc.
$14
Lilly USA, LLC
$13
Top 3 companies account for 54.9% of 2024 payments
All-time payments by company (2018-2024) ›
Biogen, Inc.
$154,307
EMD Serono, Inc.
$126,395
GENZYME CORPORATION
$109,026
Novartis Pharmaceuticals Corporation
$60,764
E.R. Squibb & Sons, L.L.C.
$38,187
Eisai Inc.
$34,590
Celgene Corporation
$30,927
Genentech USA, Inc.
$22,132
Mallinckrodt Hospital Products Inc.
$19,965
TG Therapeutics, Inc.
$17,840
TG THERAPEUTICS, INC.
$14,942
Mallinckrodt Enterprises LLC
$14,706
Janssen Pharmaceuticals, Inc
$13,866
Mallinckrodt LLC
$8,175
Alexion Pharmaceuticals, Inc.
$7,060
Merck Sharp & Dohme LLC
$4,185
Ipsen Biopharmaceuticals, Inc
$3,133
Lundbeck LLC
$2,932
Acorda Therapeutics, Inc
$2,581
ANI Pharmaceuticals, Inc.
$2,517
Greenwich Biosciences, Inc.
$2,314
Genentech, Inc.
$1,281
SK Life Science, Inc.
$1,052
Amgen Inc.
$655
ABBVIE INC.
$537
ModernaTX, Inc.
$500
Allergan Inc.
$441
Teva Pharmaceuticals USA, Inc.
$415
Exeltis, USA Inc.
$299
Allergan, Inc.
$261
PFIZER INC.
$252
Horizon Therapeutics plc
$228
Neurocrine Biosciences, Inc.
$210
Adamas Pharmaceuticals, Inc.
$198
Supernus Pharmaceuticals, Inc.
$191
Biohaven Pharmaceuticals, Inc.
$182
Sunovion Pharmaceuticals Inc.
$175
UCB, Inc.
$144
Janssen Biotech, Inc.
$119
Lilly USA, LLC
$113
Alnylam Pharmaceuticals Inc.
$109
CSL Behring
$98
ACADIA Pharmaceuticals Inc
$97
Kyowa Kirin, Inc.
$96
Xeris Pharmaceuticals, Inc.
$71
Strongbridge US INC.
$69
Amneal Pharmaceuticals LLC
$59
Avanir Pharmaceuticals, Inc.
$52
Mitsubishi Tanabe Pharma America, Inc.
$48
BANNER LIFE SCIENCES, LLC
$47
ARGENX US, INC.
$44
IMPEL PHARMACEUTICALS INC.
$43
Otsuka America Pharmaceutical, Inc.
$40
Avion Pharmaceuticals
$39
AbbVie Inc.
$38
Impax Laboratories, Inc.
$38
LivaNova USA, Inc.
$38
ARBOR PHARMACEUTICALS, INC.
$38
AstraZeneca Pharmaceuticals LP
$37
Medtronic, Inc.
$36
CATALYST PHARMACEUTICALS, INC.
$35
Vertical Pharmaceuticals, LLC
$34
Promius Pharma LLC
$33
US WorldMeds, LLC
$26
MITSUBISHI TANABE PHARMA AMERICA, INC.
$21
Upsher-Smith Laboratories LLC
$19
Axsome Therapeutics, Inc.
$18
Vanda Pharmaceuticals Inc.
$18
Catalyst Pharmaceuticals, Inc.
$18
Grifols USA, LLC
$18
Mylan Pharmaceuticals Inc.
$17
Biohaven Pharmaceutical Holding Company Ltd.
$16
Mylan Specialty L.P.
$14
Neurelis, Inc.
$14
MERZ NORTH AMERICA, INC.
$14
SANOFI-AVENTIS U.S. LLC
$11
Top 3 companies account for 55.7% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aduhelm · Aimovig · BAFIERTAM · BOTOX · BOTOX - NEUROLOGY · BOTOX THERAPEUTIC · BRIUMVI · Briviact · COMIRNATY · COPAXONE · DYSPORT · Dhivy · Dysport · EMGALITY · EVUSHELD · Enspryng · Epidiolex · Evobrutinib · FIRDAPSE · Fycompa · GILENYA · GIVLAARI · GLATIRAMER ACETATE · GOCOVRI · Gamunex-C · Glatiramer Acetate · Hizentra · Horizant · INBRIJA · INGREZZA · INTELLIS ADAPTIVESTIM · KESIMPTA · KEVEYIS · KYNMOBI · LEMTRADA · LYRICA · Leqembi · MAVENCLAD · MAYZENT · MS DISEASE STATE · Mavenclad · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nourianz · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONPATTRO · OSMOLEX ER · OXTELLAR XR · Ocrevus · Ozanimod · PLEGRIDY · PONVORY · PURIFIED CORTROPHIN GEL · Ponvory · QULIPTA · RADICAVA · REMICADE · REXULTI · RYTARY · Radicava · Rebif · SOLIRIS · Soliris · Sunosi · TECFIDERA · TEPEZZA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trudhesa · Tysabri · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VUMERITY · VYEPTI · VYVGART · XCOPRI · XEOMIN · Xadago · ZEMBRACE SYMTOUCH · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for neurology in MA.
Geographic Context
Neurologists within 10 mi
710
Per 100K population
98.0
County median income
$126,497
Nearest hospital
NORWOOD HOSPITAL
9.1 mi
9.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Napoli is a mixed practice specialist, with above-average Medicare volume (top 0% in MA), with speaking/promotional industry engagement in the top 1% of MA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Napoli experienced with ocrelizumab infusion (ocrevus) for ms?
Based on Medicare claims data, Dr. Napoli performed 33,604 ocrelizumab infusion (ocrevus) for ms services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Napoli receive payments from pharmaceutical companies?
Yes. Dr. Napoli received a total of $699,260 from 76 companies across 1,371 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Napoli's costs compare to other neurologists in Foxboro?
Dr. Napoli's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Napoli) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Foxboro
Browse neurologists in Foxboro ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in MA
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in MA
Which MA neurologists receive the most from drug and device companies.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology